Patients with STEMI and new LBBB experienced significant improvements in heart failure management, particularly with the increased use of angiotensin receptor-neprilysin inhibitor/angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ARNI/ACEi/ARB) and mineralocorticoid receptor antagonist (MRAs), reflecting a proactive approach in addressing the more severe cardiac dysfunction typically associated with LBBB. Here, ACE is linked to heart failure.